China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Transcranial temporal interference stimulation as adjunctive therapy for mild-to-moderat... Read More
China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Post-market Clinical Study of RIECS-1 System with DCSD-1111 Transmission Component for S... Read More
China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Clinical trial evaluating the effectiveness and safety of using a disposable activated l... Read More
China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Mechanisms and Intervention Strategies of School Bullying Among Middle School Students f... Read More
China, Oct. 9 -- The Chinese Clinical Trial Registry (ChiCTR) received information related to the study titled 'Association Between Erector Spinae Cross-Sectional Area and In-Hospital Mortality Risk i... Read More
Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'A Phase 1 randomized, double-blind, placebo-controlled, single-ascending-dose study investigating t... Read More
Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'A Multinational, Multicenter Study With an Open-Label Phase 1b and a Randomized, Double-Blind, Plac... Read More
Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'A Global, Multicenter, Prospective, Controlled, Open-Label Pivotal Study of Iodofalan (131I) Soluti... Read More
Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'RASolute 303: A Phase 3 Global, Multicenter, Open-label, Randomized, 3-Arm Study of Daraxonrasib Mo... Read More
Singapore, Oct. 9 -- The Health Sciences Authority received information related to the study titled 'A Multicenter, Multi-Part, Phase 1/2 Study of EIK1005 as Monotherapy and in Combination with Pembro... Read More